Table 1.
Patient demographics and disease characteristics
| Patient | Disease | Age(y) | Gender | Stage1 | Time From Diagnosis (years) | Time To Treatment (months)2 | Disease Status3 | LDT4 (months) | IGHV | VH Gene | CD38 (%) | Cytogenetic Status5 (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HW01 | CLL | 48 | F | 3 | 4 | 51 | A | 9.19 | M | VH4-34 | 2 | 13q- (93%) |
| HW02 | SLL | 59 | F | 4 | 3 | 40 | A | ND | U | VH3-09 | 39 | +12 (49%) |
| HW03 | CLL | 77 | M | 2 | 11 | 143 | S | 19.7 | U | VH1-69 | 64 | no abnormality |
| HW04 | CLL | 56 | F | 3 | 1 | 14 | A | 3.34 | U | VH4-39 | 82 | +12 (64%) |
| HW05 | CLL | 61 | M | 1 | 3 | 86 | S | ND | M | VH1-18 JH4b | 2 | no abnormality |
| HW06 | CLL | 57 | F | 3 | 2 | 38 | S | 13.55 | U | VH1-eJH3b | 43 | 13q- (8%) |
| HW07 | SLL | 75 | M | 4 | 5 | 63 | S | ND | M | VH7-04.1 | 71 | +12 (56%), 13q- (45%) |
| HW08 | CLL | 47 | M | 3 | 3 | 39 | A | 20.82 | M | VH3-74 | 8 | 17p- (16%), +12 (17%), 13q- (19%) |
| HW09 | CLL | 73 | M | 2 | 1 | 31 | S | 11.79 | M | VH3-23 | 0.8 | 11q- (9%), 13q- (60%) |
| HW11 | CLL | 55 | F | 1 | 4 | 79 | S | 24 | M | VH3-07 | 2 | 13q- (60%) |
| HW12 | SLL | 73 | F | 4 | 5 | 92 | S | ND | M | VH4-34 | ND | +12 (8%) |
| HW13 | CLL | 67 | M | 2 | 5 | 84 | S | 19.67 | U | VH3-21 | 3 | 13q- (73%) |
| HW15 | CLL | 63 | M | 1 | 1 | 16 | A | 4.86 | U | VH1-eJ6b | 81 | +12 (62%), 13q- (7%) |
| HW18 | CLL | 33 | M | 2 | 1 | 11 | A | ND | U | VH1-69 | 0.7 | p53 mutation* |
| HW20 | CLL | 69 | F | 2 | 1 | 8 | A | 2.74 | U | VH3-30 | 0.9 | 17p- (43%) |
F, Female; M, Male; Mu, Mutated; U, Unmutated; ND, Not done
Rai Staging for patients with CLL and Ann Arbor Staging System for patients with SLL
Time to treatment is calculated from time of diagnosis to initiation of treatment or last follow-up for patients with stable disease where treatment indications have not been met.
Disease status by IWCLL guidelines; A, Active disease, treatment indicated; S, Stable disease, no treatment indicated.
Lymphocyte doubling time. LDT is not applicable for SLL patients and not available for HW05 who had no change in ALC during the observation period and HW18 as there were only two time points available.
Cytogenetic status was determined by FISH on peripheral blood cells
This patient was included in the analyses for 17p-